What to know about GLP-1s and cannabis use
A nationwide recall of GLP-1 injections has been issued due to sterility concerns. The recall affects several products, including Mounjaro and Zepbound. Separately, there is growing interest in the interaction between GLP-1s and cannabis use, particularly regarding the impact on appetite and weight loss. The relationship between GLP-1 receptor agonists and cannabinoids is complex and not fully understood.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ GLP-1 injections have been recalled nationwide due to sterility concerns.
- ✓ The recall affects several products, including Mounjaro and Zepbound.
- ✓ Cannabinoids interact with incretin mimetics and GLP-1 receptor agonists primarily through non-enzymatic pharmacokinetic interactions.
What changed
The FDA has recalled several GLP-1 products due to sterility concerns, and there is increasing attention to the interaction between GLP-1s and cannabis use.
Live updates
-
GLP-1 recall and cannabis use interactions raise concerns
A nationwide recall of GLP-1 injections has been issued due to sterility concerns. The recall affects several products, including Mounjaro and Zepbound. Separately, there is growing interest in the interaction between GLP-1s and cannabis use, particularly regarding the impact on appetite and weight loss. The relationship between GLP-1 receptor agonists and cannabinoids is complex and not fully understood.
Why it matters
GLP-1 receptor agonists are used to treat type 2 diabetes and obesity. Cannabis use has been reported to affect appetite and metabolism. The interaction between these two substances is not well understood, and further research is needed to determine the potential risks and benefits.
What is confirmed
- GLP-1 injections have been recalled nationwide due to sterility concerns.
- The recall affects several products, including Mounjaro and Zepbound.
- Cannabinoids interact with incretin mimetics and GLP-1 receptor agonists primarily through non-enzymatic pharmacokinetic interactions.
Still unconfirmed
- The interaction between GLP-1s and cannabis use may impact appetite and weight loss.
What to watch next
- Further research on the interaction between GLP-1s and cannabis use
- FDA updates on the recall of GLP-1 products
- Clinical trials on the safety and efficacy of combining GLP-1s and cannabis
confidence 75%Sources used for this update (14)
- gardnermagazine.com — Deep Dive Episodes – Gardner Magazine – Gardner News Magazine: Local News & Articles in Gardner MA
- USA Today — GLP-1 injections recalled nationwide. See affected products
- Fox Business — GLP-1 injections recalled nationwide over sterility concerns
- MassLive — GLP-1 recall: Mounjaro, Zepbound ingredient risk raised to second-highest level
- LiveNOW from FOX — What to know about GLP-1s and cannabis use
- The Boston Globe — Compounded GLP-1 drugs recalled amid rising concerns over unapproved weight-loss alternatives
- www.rova.nz — The Peter Attia Drive | Podcasts | rova
- www.fox4news.com — FDA recalls GLP-1 drug, other injectable medication over sterility concerns | FOX 4 Dallas-Fort Worth
- explodingtopics.com — 44 Trending Products to Sell (2026)
- www.psychiatrictimes.com — Understanding the Relationship Between Cannabidiol and Psychosis: Clinical Issues | Psychiatric Times
- www.news-medical.net — Antibody patterns may predict inflammatory bowel disease years before diagnosis - Medical News ,Medical Articles
- cedclinic.com — Cannabinoids & Incretin Mimetics & GLP-1 Receptor Agonists ...
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community